Efficacy and Safety of Canakinumab in Patients with TNF Receptor Associated Periodic Syndrome

被引：0
|
作者：
Gattorno, Marco [1 ]
Obici, Laura [2 ]
Meini, Antonella
Tormey, Vincent [3 ]
Abrams, Ken [4 ]
Davis, Nicole [4 ]
Andrews, Christopher [5 ]
Lachmann, Helen J. [6 ]
机构：
[1] Ist Giannina Gaslini, I-16148 Genoa, Italy
[2] IRCCS Policlin San Matteo, Pavia, Italy
[3] Galway Univ Hosp, Galway, Ireland
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Pharmaceut UK Ltd, Surrey, England
[6] UCL, Sch Med, London W1N 8AA, England
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
749
引用
收藏
页码：S322 / S322
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TNF RECEPTOR ASSOCIATED PERIODIC SYNDROME (TRAPS)
    Gattorno, M.
    Obici, L.
    Meini, A.
    Tormey, V.
    Abrams, K.
    Davis, N.
    Andrews, C.
    Lachmann, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 289 - 289
  • [2] EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH ACTIVE RECURRENT OR CHRONIC TNF-RECEPTOR ASSOCIATED PERIODIC SYNDROME (TRAPS)
    Lachmann, H.
    Cattalini, M.
    Obici, L.
    Barcellona, R.
    Speziale, A.
    Joubert, Y.
    Junge, G.
    Gattorno, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 852 - 853
  • [3] Long-Term Efficacy and Safety of Canakinumab in Patients with Active Recurrent or Chronic TNF Receptor-Associated Periodic Syndrome
    Gattorno, Marco
    Cattalini, Marco
    Obici, L.
    Barcellona, Roberto
    Speziale, Antonio
    Joubert, Yolandi
    Junge, Guido
    Lachmann, Helen
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [4] Canakinumab for the treatment of TNF-receptor associated periodic syndrome
    La Torre, F.
    Caparello, M. C.
    Cimaz, R.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (06) : 513 - 523
  • [5] Canakinumab for the treatment of TNF-receptor associated periodic syndrome (TRAPS)
    Soliani, Martina
    Cattalini, Marco
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (10): : 833 - 838
  • [6] Efficacy of canakinumab for mosaic tumor necrosis factor receptor associated periodic syndrome
    Terre, Alexandre
    Vautier, Mathieu
    Kahn, Jean -Emmanuel
    Georgin-Lavialle, Sophie
    Boursier, Guilaine
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 123 : 156 - 158
  • [7] A Japanese case of TNF receptor-associated periodic syndrome (TRAPS) successfully treated by canakinumab
    Yoshimura, Motoki
    Mitoma, Hiroki
    Kimoto, Yasutaka
    Oryoji, Daisuke
    Otsuka, Yukimi
    Wang, Qiaolei
    Inokuchi, Shoichiro
    Ayano, Masahiro
    Akahoshi, Mitsuteru
    Arinobu, Yojiro
    Niiro, Hiroaki
    Kusuhara, Koichi
    Horiuchi, Takahiko
    MODERN RHEUMATOLOGY CASE REPORTS, 2019, 3 (01) : 49 - 52
  • [8] Efficacy of etanercet for the treatment of patients with TNF receptor-associated periodic syndrome (TRAPS).
    Hull, KM
    Aksentijevich, I
    Singh, H
    Dean, J
    Yarboro, C
    O'Shea, JJ
    Kastner, DL
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S378 - S378
  • [9] Periocular oedema and conjunctivitis secondary to incomplete response to canakinumab in a patient with periodic syndrome associated to TNF receptor
    Romero-Caballero, Maria Dolores
    MEDICINA CLINICA, 2021, 157 (07): : 348 - 349
  • [10] Efficacy and Safety of Canakinumab in Patients with Cryopyrin Associated Periodic Syndrome: Results From Meta-Analysis of 5 Studies
    Lachmann, Helen J.
    Kuemmerle-Deschner, Jasmin B.
    Heike, Toshio
    Hara, Toshiro
    Yokota, Shumpei
    Mckernan, Phil
    Widmer, Albert
    Davis, Nicole
    Hachulla, Eric
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S321 - S322
12345